Patent intelligence · US
US 11707447
C4-carbonothioate-substituted tryptamine derivatives and methods of using
C4-carbonothioate-substituted tryptamine derivatives and methods of using
Patent details — US 11707447
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 25, 2023
- Expiration
- Jul 20, 2043
- Applicant
- Enveric Biosciences Canada Inc.
- Claims
- 13
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
Quick answer
US 11707447 (C4-carbonothioate-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enveric Biosciences Canada Inc.
- Grant date
- Expiration
- Claims
- 13
- CPC classes
- A61K, A61K31/4045, A61P, A61P25/00
More from Enveric Biosciences Canada Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428408
Fused heterocyclic mescaline derivatives
granted -
US 12378195
Aminated psilocybin derivatives and methods of using
granted -
US 12358885
Substituted n-propylamine fused heterocyclic mescaline derivatives
granted -
US 12338231
N-heterocycle substituted tryptamine derivatives and methods of using
granted -
US 12195439
C1-substituted isopropylamine fused heterocyclic mescaline derivatives
granted -
US 12187679
Hydroxylated psilocybin derivatives and methods of using
granted -
US 12138276
Halogenated psilocybin derivatives and methods of using
granted -
US 12133856
Multi-substituent psilocybin derivatives and methods of using
granted
Frequently asked questions
What is US patent 11707447?
US 11707447 (C4-carbonothioate-substituted tryptamine derivatives and methods of using) is held by Enveric Biosciences Canada Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11707447?
Enveric Biosciences Canada Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 22 pharmaceutical patents for this assignee.
When does US 11707447 expire?
Our index shows an expiration date of Jul 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.